Cargando…

Real-world safety and effectiveness of nivolumab for recurrent or metastatic head and neck cancer in Japan: a post-marketing surveillance

BACKGROUND: On the basis of phase III CheckMate 141 results, nivolumab was approved for recurrent or metastatic head and neck cancer after undergoing platinum-containing chemotherapy in Japan. This post-marketing surveillance aimed to evaluate the safety and effectiveness of nivolumab for head and n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tahara, Makoto, Kiyota, Naomi, Nibu, Ken-ichi, Akamatsu, Ayumi, Hoshino, Tomohiro, Hayashi, Ryuichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364900/ https://www.ncbi.nlm.nih.gov/pubmed/34110532 http://dx.doi.org/10.1007/s10147-021-01949-1

Ejemplares similares

Safety and effectiveness of nivolumab in Japanese patients with malignant melanoma: Final analysis of a post‐marketing surveillance
por: Uhara, Hisashi, et al.
Publicado: (2022)

Real‐world safety of nivolumab in patients with non‐small‐cell lung cancer in Japan: Postmarketing surveillance
por: Yamamoto, Nobuyuki, et al.
Publicado: (2021)

Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma
por: Kubota, Hikaru, et al.
Publicado: (2021)

Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
por: Takahashi, Shunji, et al.
Publicado: (2020)

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141
por: Gillison, Maura L, et al.
Publicado: (2022)

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Phase II trial of chemoradiotherapy with S-1 plus cisplatin for unresectable locally advanced head and neck cancer (JCOG0706)
por: Tahara, Makoto, et al.
Publicado: (2015)

Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance
por: Uemura, Hirotsugu, et al.
Publicado: (2022)

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2020)

Low-Dose vs. High-Dose Cisplatin: Lessons Learned From 59 Chemoradiotherapy Trials in Head and Neck Cancer
por: Szturz, Petr, et al.
Publicado: (2019)

A laryngeal closure technique for the treatment of patients with head and neck cancer
por: Furukawa, Tatsuya, et al.
Publicado: (2019)

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)
por: Yen, Chia‐Jui, et al.
Publicado: (2020)

Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
por: Tsushima, Nayuta, et al.
Publicado: (2020)

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
por: Saba, Nabil F., et al.
Publicado: (2019)

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
por: Haddad, Robert I., et al.
Publicado: (2023)

Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
por: Nishikawa, Daisuke, et al.
Publicado: (2018)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma
por: Tahara, Makoto, et al.
Publicado: (2021)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma
por: Morimoto, Hiroyuki, et al.
Publicado: (2017)

Toxic epidermal necrolysis associated with nivolumab treatment for head and neck cancer
por: Koshizuka, Keiichi, et al.
Publicado: (2020)

Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan
por: Tahara, Makoto, et al.
Publicado: (2020)

A Multicenter Phase II Trial of Docetaxel, Cisplatin, and Cetuximab (TPEx) Followed by Cetuximab and Concurrent Radiotherapy for Patients With Local Advanced Squamous Cell Carcinoma of the Head and Neck (CSPOR HN01: ECRIPS Study)
por: Zenda, Sadamoto, et al.
Publicado: (2019)

Successful Treatment of Refractory Squamous Cell Cancer of the Head and Neck with Nivolumab and Ipilimumab
por: Schwab, Katjana S., et al.
Publicado: (2018)

Unexpected Response to Nivolumab in a “Fast Progressor” Head and Neck Cancer Patient
por: Napolitano, Martina, et al.
Publicado: (2019)

Efficacy and Safety of Nivolumab Plus Ipilimumab vs Nivolumab Alone for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: The Phase 2 CheckMate 714 Randomized Clinical Trial
por: Harrington, Kevin J., et al.
Publicado: (2023)

Radiotherapy for Stage I or II hypopharyngeal carcinoma
por: Nishimura, Hideki, et al.
Publicado: (2012)

Roles of skull base surgery and particle radiotherapy for orbital malignant tumors involving the skull base
por: Teshima, Masanori, et al.
Publicado: (2021)

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
por: Kakimoto, Yoshihide, et al.
Publicado: (2021)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemotherapy: a postmarketing surveillance study
por: Yamaguchi, Kensei, et al.
Publicado: (2021)

Successful Management of Aggressive Fibromatosis of the Neck: A Case Report
por: Avinçsal, Özgür Mehmet, et al.
Publicado: (2018)

Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab
por: Minohara, Kiyoshi, et al.
Publicado: (2021)

Trends in the incidence of head and neck cancer by subsite between 1993 and 2015 in Japan
por: Kawakita, Daisuke, et al.
Publicado: (2022)

Oncolytic effect of Midkine promoter–based conditionally replicating adenoviruses expressing EGFR siRNA in head and neck squamous cancer cell line T891
por: Uehara, Natsumi, et al.
Publicado: (2020)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

[18F]Fluorodeoxyglucose uptake by positron emission tomography predicts outcomes for oropharyngeal and hypopharyngeal cancer treated with definitive radiotherapy
por: Ishihara, Takeaki, et al.
Publicado: (2017)

Transoral surgery for superficial head and neck cancer: National Multi‐Center Survey in Japan
por: Katada, Chikatoshi, et al.
Publicado: (2021)

Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck
por: Hanna, Glenn J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_stqv5ihplaln0egmf2kka1u5hv